Smith & Nephew SNATS, Inc. (NYSE:SNN) Stock Has Consensus Price Target of $31.91 According to Brokerages

Smith & Nephew SNATS, Inc. (NYSE:SNN) has been assigned an average recommendation of “Hold” from the twelve analysts that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, ten have issued a hold recommendation and one has issued a buy recommendation on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $31.91.

SNN has been the subject of a number of analyst reports. Wall Street Zen raised shares of Smith & Nephew SNATS from a “hold” rating to a “buy” rating in a research report on Sunday, September 13th. BTIG Research began coverage on shares of Smith & Nephew SNATS in a research report on Monday, August 31st. They set a “neutral” rating on the stock. Morgan Stanley cut shares of Smith & Nephew SNATS from an “overweight” rating to an “equal weight” rating in a research note on Wednesday, September 2nd. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Smith & Nephew SNATS in a report on Thursday, August 6th. Finally, Kepler Capital Markets lowered Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a research note on Thursday, June 4th.

Smith & Nephew SNATS Trading Up 0.7%

Shares of SNN stock opened at $27.09 on Tuesday. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.14 and a quick ratio of 1.11. The firm has a 50-day moving average price of $29.26 and a 200 day moving average price of $30.51. Smith & Nephew SNATS has a twelve month low of $26.40 and a twelve month high of $37.51.

Smith & Nephew SNATS Dividend Announcement

The firm also recently announced a dividend, which will be paid on Friday, November 6th. Investors of record on Friday, October 2nd will be paid a $0.3120 dividend. This represents a yield of 205.0%. The ex-dividend date is Friday, October 2nd.

Hedge Funds Weigh In On Smith & Nephew SNATS

Several large investors have recently added to or reduced their stakes in the business. Equity Investment Corp increased its position in shares of Smith & Nephew SNATS by 3.9% during the fourth quarter. Equity Investment Corp now owns 7,502 shares of the medical equipment provider’s stock worth $246,000 after acquiring an additional 285 shares during the last quarter. Cary Street Partners Financial LLC grew its stake in Smith & Nephew SNATS by 1.8% during the 4th quarter. Cary Street Partners Financial LLC now owns 20,255 shares of the medical equipment provider’s stock valued at $665,000 after purchasing an additional 365 shares in the last quarter. Parallel Advisors LLC grew its stake in Smith & Nephew SNATS by 20.0% during the 1st quarter. Parallel Advisors LLC now owns 2,322 shares of the medical equipment provider’s stock valued at $74,000 after purchasing an additional 387 shares in the last quarter. Clearstead Trust LLC purchased a new stake in Smith & Nephew SNATS during the 2nd quarter worth approximately $25,000. Finally, BKM Wealth Management LLC increased its holdings in Smith & Nephew SNATS by 2.5% during the 1st quarter. BKM Wealth Management LLC now owns 18,462 shares of the medical equipment provider’s stock worth $587,000 after purchasing an additional 451 shares during the last quarter. 25.64% of the stock is currently owned by hedge funds and other institutional investors.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company headquartered in the United Kingdom. Founded in 1856 by Thomas James Smith in Hull, the company initially operated as a pharmacy business before expanding into healthcare products and medical devices.

The company develops and manufactures technologies used in orthopaedic reconstruction, sports medicine, and advanced wound management. Its products include joint replacement systems, trauma and extremities devices, arthroscopic equipment, surgical repair technologies, wound dressings, negative-pressure wound therapy systems, and other products designed to support tissue healing and surgical care.

Smith & Nephew serves hospitals, healthcare professionals, and patients in markets around the world.